Loading
Niagen Bioscience, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 17 Nov 2025.
Niagen Bioscience, Inc.: what insiders have been doing
This page follows insider dealings at Niagen Bioscience, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Niagen Bioscience, Inc. logged 5 filings by 3 insiders.
No insider sold shares on the market over the period. Instead, the filings list 1 purchase totalling €26k, made by 1 insider. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 1 finance chief. Biggest ticket of the year: €26k, bought by Pamir Ozan and made public on 17 November 2025.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 5 filings here. The full history, which starts in 2016, counts 14 purchases against 2 sales.
The latest purchase dates back some time: it was published 335 days ago, on 17 November 2025. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 8 days. US insiders must file a Form 4 within two business days of a trade.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
24
Thresholds
n/a
Buy Volume
€2M
14 ops. · all time
Sell Volume
n/a
2 ops. · all time
Who traded when
BuySaleOzan Pamir2 buys
Carlos Luis Lopez1 buy
Since the insiders bought
- -23.3%Entry US$6.86 · Close at T+90 US$5.26
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Niagen Bioscience, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$12.08.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 2,048 of 24,161 companies
75.2
score / 100
Value66
Quality84
FCF yld6.7%
Earn yld8.8%
EV/EBITDA12.8x
ROE22%
Gross mgn64%
Net mgn13%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.49
Analyst consensus
6 analystsStrong buy
US$8.50Target US$12.08(+385%)US$22.00
Income statement
RevenueUS$129.4M
Gross profitUS$83.2M64% margin
EBITDAUS$15.7M12% margin
Net incomeUS$17.4M12.4% margin
Valuation
PER (trailing)13.1x
PER (forward)-41.5x
P/Book2.4x
Beta2.02
Balance sheet & cash
Market capUS$198.3M
Total debtUS$2.8M
Free Cash FlowUS$13.2M
Debt / Equity3%
Profitability & ownership
ROE21.8%
ROA5.4%
% insiders29.5%
% institutions41.6%
Last declaration on 8 July 2026
Declarations24 total
1,106 shares@ US$2.710.0012% mcap1.1% of flowCommon StockSEC:0001417952-26-000002:0
2,314 shares@ US$2.710.0026% mcap100.0% of flowCommon StockSEC:0002042509-26-000001:0
4,255 shares@ US$2.710.0048% mcap27.9% of flowCommon StockSEC:0001834681-26-000001:0
20,000 shares@ US$2.610.021% mcap18.0% of flowCommon StockSEC:0001417952-26-000001:0
4,464.962 shares@ US$6.8172.1% of flowCommon StockSEC:0001834681-25-000005:0
Canonical exit: 12 Feb 2026 (T+90)
66,667 shares@ US$3.3080.9% of flowCommon StockSEC:0001628280-25-017223:0
273 shares@ US$7.86100.0% of flowCommon StockSEC:0001628280-25-011466:0
Canonical exit: 5 Jun 2025 (T+90)
50,001 shares@ US$3.6694.1% of flowCommon StockSEC:0001628280-24-051264:0
2,907.197 shares@ US$7.36100.0% of flowCommon StockSEC:0001628280-24-049079:0
Canonical exit: 20 Feb 2025 (T+90)
3,000 shares@ US$1.64100.0% of flowCommon StockSEC:0001628280-24-038470:0
11,408,715 sharesCommon StockSEC:0000950170-24-099383:0
11,408,715 sharesCommon StockSEC:0000950170-24-099382:0
Canonical exit: 18 Nov 2024 (T+90)
5,000 shares@ US$1.41100.0% of flowCommon StockSEC:0001628280-23-040625:0
Canonical exit: 29 Feb 2024 (T+90)
3,467,778 sharesCommon StockSEC:0000899243-23-018667:0
Canonical exit: 5 Dec 2023 (T+90)
22,436 sharesCommon StockSEC:0001628280-23-029599:0
7,000 shares@ US$1.695.9% of flowCommon StockSEC:0001628280-23-021978:0
Canonical exit: 10 Sept 2023 (T+90)
7,000 shares@ US$1.424.3% of flowCommon StockSEC:0001628280-23-020508:0
Canonical exit: 29 Aug 2023 (T+90)
7,000 shares@ US$1.46100.0% of flowCommon StockSEC:0001628280-23-020112:0
Canonical exit: 23 Aug 2023 (T+90)
960,000 shares@ US$1.2592.8% of flowCommon StockSEC:0000899243-22-032394:0
Canonical exit: 29 Dec 2022 (T+90)
80,000 shares@ US$1.2547.2% of flowCommon StockSEC:0001628280-22-025915:0
Canonical exit: 29 Dec 2022 (T+90)
60,037 shares@ US$1.66367.2% of flowCommon StockSEC:0000899243-22-023253:0
Canonical exit: 14 Sept 2022 (T+90)
25,000 shares@ US$2.1622.9% of flowCommon StockSEC:0001628280-22-006443:0
Canonical exit: 14 Jun 2022 (T+90)
10,000 shares@ US$6.6525.6% of flowCommon StockSEC:0001415889-21-002499:0
Canonical exit: 11 Aug 2021 (T+90)
5,063 sharesCommon StockSEC:0001415889-16-004790:0
24 of 24 declarations
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. (NASDAQ: NAGE) is a U.S.-based biosciences company headquartered in Los Angeles, California, United States. The company originated as ChromaDex and adopted its current name on March 19, 2025, reflecting a strategic shift toward NAD+ science and healthy aging. Its business has been built around Niagen®, a patented form of nicotinamide riboside (NR), a precursor to NAD+ that the company positions as a scientifically validated ingredient for cellular metabolism and longevity-related applications. Niagen Bioscience now presents itself as a science-led company combining intellectual property, research collaborations, and commercialization of evidence-based products. ([investors.niagenbioscience.com](https://investors.niagenbioscience.com/news/news-details/2025/ChromaDex-Evolves-Into-Niagen-Bioscience-Marking-a-New-Era-of-Uncovering-the-Potential-of-NAD-With-Precision-Science/default.aspx?utm_source=openai))
The company’s model is organized around three main activities. First is consumer health, led by Tru Niagen®, its flagship oral supplement brand. Second is the ingredients segment, which supplies food-grade and pharmaceutical-grade Niagen® to third-party manufacturers and, in the pharmaceutical channel, to authorized 503B outsourcing facilities. Third is the analytical reference standards and services business, a legacy activity that the company is now strategically exiting through the announced sale of substantially all of those assets. This divestiture underscores a clear focus on NAD+ science, IP monetization, and commercial growth in the longevity sector. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001386570/000138657026000013/cdxc-20251231.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Niagen Bioscience differentiates itself through a science-heavy brand, a broad patent portfolio around NR, and an extensive global research network. The company describes Tru Niagen as the leading NAD+ boosting oral supplement in the United States based on revenue data from the major U.S. e-commerce marketplace for the referenced period. It also aims to deepen its platform through higher-value formats such as Niagen IV and injectable products, which broadens the commercial opportunity beyond the core supplement business. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1386570/000138657025000015/pressreleasedatedoctober62.htm?utm_source=openai))
Recent news has emphasized both product expansion and scientific validation. Niagen Bioscience launched Tru Niagen Beauty and, in 2026, introduced a Niagen Skincare Innovation Lab and the limited-release Niagen NanoCloud™ topical product, extending the Niagen ingredient story into skincare. The company has also highlighted clinical and research milestones in long COVID, Parkinson’s disease, and external research agreements, reinforcing its positioning as a platform that converts scientific credibility into commercial optionality. Geographically, the group operates from the United States but has an international footprint through research partnerships, product distribution, and global collaborations. For investors, the stock combines consumer health exposure, a healthy-aging thesis, and a NASDAQ-listed scientific growth story. ([investors.niagenbioscience.com](https://investors.niagenbioscience.com/news/news-details/2026/Niagen-Bioscience-Launches-Niagen-Skincare-Innovation-Lab-and-Debuts-Dermatologist-Tested-Niagen-NanoCloud-From-Tru-Niagen-Powered-by-Patented-Niagen/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
